The E2100 trial: first-line Avastin^© and paclitaxel in previously untreated mBC

ECOG 4599: trial design⁵

• Phase III trial evaluating Avastin^© 15mg/kg combined with paclitaxel/carboplatin in chemotherapy-naïve patients with advanced non-squamous NSCLC.
• All patients received six cycles of paclitaxel 200mg/m² plus carboplatin AUC 6 and were randomised to one of
  • chemotherapy alone (n=444)
  • Avastin^© 15mg/kg every 3 weeks plus chemotherapy until PD (n=434).⁵

• Primary endpoint.
  • OS.
• Secondary endpoints.
  • PFS.
  • ORR.
  • duration of response.
  • selected AEs.

ECOG 4599: first-line Avastin^© -based therapy – the first combination to achieve OS beyond the historical benchmark of 1 year.

Avastin^© -based therapy extends survival beyond conventional paclitaxel/carboplatin chemotherapy, with OS >1 year